• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » UPDATE: FDA panel hands Medtronic a narrow win

UPDATE: FDA panel hands Medtronic a narrow win

October 9, 2013 By Ingrid Mezo

UPDATE: FDA panel hands Medtronic a narrow win

A panel of experts yesterday narrowly recommended that the FDA expand indications for all Medtronic (NYSE:MDT) pulse generators already on the market, adding labeling to treat patients at risk of developing new or worsened heart failure due to their need for right ventricular pacing.

The FDA’s Circulatory System Devices Panel voted 4-3, with 1 abstention, that the benefits of programming patients for bi-ventricular pacing using Medtronic pulse generators outweigh the risks.

Dr. David Steinhaus, Medtronic’s general manager for heart failure and medical director for its cardiac rhythm disease management business, told MassDevice.com that he was pleased with the outcome of the advisory panel meeting.

"As the longest-running trial of its kind, Block HF has shown superior long-term outcomes of bi-ventricular pacing for these patients," Steinhaus told us. "As the regulatory process continues, we look forward to working with the FDA to expand the use of our CRT devices to treat this specific patient population."

Panelists were split on the benefits of programming patients for bi-ventricular pacing because the study to support the expanded indication did not take certain risks into account, including shorter generator life, which involves more generator changes, and an increased risk of infection with every generator change.

"With this study, I don’t think we can really quantify the risks of the [left ventricular dysfunction] all that much … so I think the risks are more significant than they are if we just look at the risks we’ve been presented today," Dr. Patricia Kelly of Community Medical Center in Missoula, Mont., said.

"If you take all people with heart failure and do bi-ventricular pacing, it’s not helpful. If you take all people with left bundle branch block, it’s not helpful. But if you take those with left bundle branch block and heart failure, it’s helpful. We found that many of the these patients are New York Heart Assn. Class I and their annual mortality is only about 6%, so I think that what we have here is a lower-risk population and in that, I’m not sure that the benefit of the procedure outweighs the risk," Dr. Richard Lange of University of Texas in San Antonio added.

Panelists were unanimous that these devices were effective when programmed for bi-ventricular pacing, and voted 6-1 that they are safe.

The expanded indication, which Medtronic announced earlier this year that it would pursue, applies to all of the company’s market-cleared cardiac resynchronization therapy pacemaker and cardiac resynchronization therapy defibrillator devices. Expanded indication was supported by the medtech giant’s Block HF trial.

More than 1 million Americans have AV block, which reduces the heart’s ability to properly function by blocking the electrical signals between its top and bottom chambers, Medtronic said in a press release. While RV pacing helps restore heart function in patients with AV block, studies suggest that in patients with both AV block and LV dysfunction, this type of pacing may escalate the progression of heart failure. Heart failure will cost the U.S. for an estimated $32 billion in 2013, with projections showing a 120% increase in cost by 2030 for a total of $70 billion.

Panelists mull meaning of Block HF trial data

The Block HF study aimed to demonstrate that heart failure patients programmed for bi-ventricular pacing lived longer, notched fewer urgent care visits and experienced significant increase in left ventricular end systolic volume index, as compared with patients programmed for right ventricular pacing.

Medtronic’s CRT-P devices are currently approved for use in patients with marked-to-severe heart failure. The company’s CRT-D devices are currently approved for patients at risk of developing life-threatening ventricular arrhythmias and who have either mild or severe heart failure.

The Medtronic pulse generators in question include both those with defibrillation capabilities and those without, and both types require implantation of at least a right ventricular and a left ventricular lead in order for sensing and pacing to work. The RV lead used with a CRT-D device can also deliver high voltage energy. Clinicians have discretion in whether to implant a right atrial lead for both devices.

"The results of Block HF offer us a potential new treatment paradigm for heart failure patients with AV block," lead investigator Dr. Anne Curtis of the Medicine Dept. at the University at Buffalo School of Medicine and Biomedical Sciences in New York said in the release. "This new approach could fill an unmet need for these patients."

Although the prospective, multi-site, randomized, double-blinded, parallel-controlled Block HF met its primary objective, the FDA had questions about the clinical meaning of increase in left ventricular end systolic volume index demonstrated by the study. LVESVI events accounted for more than half of the primary endpoint events in the Block HF analysis, the agency noted in its executive summary posted ahead of the meeting.

The FDA questioned the significance of a change in LVESVI, because an increased LVESVI does not seem to strongly predict future heart failure urgent care events or death, the panelists said. And, when LVESVI is excluded from an exploratory analysis of Block HF’s primary objective, the magnitude of benefit observed is reduced.

The panel had mixed perspectives on the clinical meaning of an increase of greater than or equal to 15% LVESVI and the impact of LVESVI events on the success of the study. Some panelists said the change in LVESVI was not meaningful, while others said it had limited meaning, but the degree and importance were unclear.

"In terms of the importance of the finding, at least we’re reassured that it goes the way we would expect it to go in terms of evident benefit for bi-ventricular pacing. In terms of, if this were not included, likewise there’s comment from the panel that there is consistency in the signals that we’re seeing that we believe that at least the heart failure finding appears not universally, but the majority take that as a clinically relevant finding," Dr. Richard Page of the University Wisconsin School of Medicine & Public Health in Madison said. "The data set are satisfactory from a statistical standpoint."

Piedmont Heart Institute’s Dr. David Kandzari pointed out that LVESVI has been demonstrated to have clinical meaning in other studies, just not in Block HF.

"I don’t think we can readily discount the role of LV end systolic volume index, as previous trials have shown it to be predictive. It just wasn’t in this trial," Kandzari said. "We would expect a beneficial therapy that could reduce mortality and heart failure to also improve indices that have traditionally been related to heart failure and this is 1 of them. I think if the LV and systolic volume actually worsened, we perhaps wouldn’t be sitting here today."

Medtronic proposed expanding treatment indications for its pace generators to include New York Heart Assn. Class I, II and III heart failure, patients with pacemaker-indicated 1st-, 2nd- or 3rd-degree AV block.

But the panel suggested the FDA remove some of the proposed indications and exclude patients with 1st-degree AV block and documented Wenckebach or PR interval of more than 300 ms when paced at 100 ppm, to ensure that benefits of bi-ventricular programmed pace generators outweigh the risks.

In addition, panelists recommended the FDA ask Medtronic to gather data in a post-approval study of bi-ventricular pacing in its pulse generators that is larger than 300 patients. The post-approval study should include Class I indications, women and minorities, and examine whether patients are optimized in real-world clinical care. It should also address whether epicardial LD leads are being placed and what the results are from that surgical intervention, panelists noted.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Cardiac Rhythm Management

In case you missed it

  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
  • Teleflex wins Health Canada nod for Manta vascular closure device
  • Study shows strong performance, improved outcomes with Medtronic Evolut TAVR
  • New FDA clearance expands indications for Xact Robotics’ ablation system
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy

RSS From Medical Design & Outsourcing

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS